Key Drivers
- Margin Expansion
- Strong Liquidity
- Higher Debt
AIAI Summary
ADMA has evolved into a cash-generative specialty biologics name with strong ASCENIV-driven margins and FCF, but the withdrawal of long-term guidance and class-action/internal-control allegations create a material governance discount that likely caps re-rating until trust and disclosure improve.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Expansion
- •Strong Liquidity
- •Higher Debt
ADMA is showing stronger profitability, cash generation, and liquidity, but the benefit is partly offset by higher debt and a now-less-conservative balance sheet.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Support holding
- •Resistance stalls
ADMA has trended higher over the last month with higher lows and support at $8.30-$8.40, but repeated stalls near $8.75-$9.00 mean a clean breakout above $9.00 is still needed.
Late-June pullback from $8.75 to $8.37 showed momentum is improving but not yet secure
Sentiment & News
Key News Insights:
- •Lead plaintiff deadline
- •Revenue allegations
- •Internal control concerns
ADMA Biologics is facing sustained securities class action scrutiny over alleged revenue inflation, related-party transactions, and weak internal controls, with investor lead-plaintiff deadlines running to 2026-08-10.
The ongoing lawsuit headlines create a legal overhang that could weigh on ADMA sentiment until the case progresses or is resolved
Similar Companies in Healthcare
Other companies in the same sector with AI ratings